Cheetah Medical Announces Supplier Agreement with Allina Health
NEWTON, Mass.–(BUSINESS WIRE)–Cheetah Medical has signed a supplier contract with Allina Health, a leading non-for-profit healthcare system serving communities throughout Minnesota and western Wisconsin. The contract enables Allina Health facilities to have access to Cheetah Medical’s hemodynamic monitoring solutions to guide volume management decisions in septic patients across the Allina Health hospital network.
“Intravenous fluid requirements vary significantly between patients based on underlying health conditions, and it can be a challenge to determine the right amount of fluid needed to properly maintain organ perfusion and optimize care,” said Jeff Dichter, MD, Medical Director of Allina Health’s sepsis program. “The Cheetah Medical technology has demonstrated value in addressing this challenge and we have made it a part of our system-wide sepsis management protocol at Allina Health.”
Doctors and nurses know that administering the correct amount of fluid is important. Insufficient fluid can lead to tissue hypoxia and poor perfusion.1-3 On the other hand, too much fluid is associated with organ failure, increased ventilator days and increased time in the ICU.4-7 Recent studies show that volume overload in septic patients is associated with an increased risk of mortality8, and careful management of intraoperative fluids can greatly enhance patient outcomes in surgery.5
Cheetah Medical hemodynamic monitoring technologies are 100% non-invasive, and provide dynamic assessments of fluid responsiveness, which enables clinicians to make more confident and informed treatment decisions about the right amount of fluid to administer to maintain adequate organ perfusion.
“We are proud to be working with Allina Health, and system wide relationships like we enjoy with Allina Health have driven significant growth for Cheetah Medical over the past couple years,” said Chris Hutchison, President and Chief Executive Officer for Cheetah Medical. “Our products significantly reduce the barriers of bringing advanced hemodyamic monitoring to patients in the emergency, critical care and surgical settings. We believe that our technology can help Allina Health address the volume management challenges associated with sepsis.”
Cheetah is also expanding its presence outside the United States, and the company has signed new distribution agreements covering 20 countries in the past 12 months, including Japan, Spain, and multiple countries in southeast Asia and Eastern Europe. Cheetah Medical now has sales in more than 25 countries worldwide.
About Allina Health
Allina Health is dedicated to the prevention and treatment of illness and enhancing the greater health of individuals, families and communities throughout Minnesota and western Wisconsin. A not-for-profit health care system, Allina Health cares for patients from beginning to end-of-life through its 90+ clinics, 14 hospitals, 14 pharmacies, specialty care centers and specialty medical services that provide home care, senior transitions, hospice care, home oxygen and medical equipment, and emergency medical transportation services. To learn more, please visit www.allinahealth.org
About Cheetah Medical
Cheetah Medical is the pioneer and global leading provider of 100% noninvasive hemodynamic monitoring technologies that are designed for use in critical care, operating room and emergency department settings. The CHEETAH NICOM™ & STARLING™ SV technologies use a proprietary algorithm to calculate parameters related to the volume of blood and functioning of the patients’ circulatory system. Medical professionals use this information to assess patients’ unique volume requirements to guide volume management decisions and to maintain adequate organ perfusion. Cheetah Medical technologies are designed to enable more confident and informed therapy decisions that support the clinical goals of improving patient outcomes and driving economic efficiencies. To learn more, please visit www.cheetah-medical.com
1. Shoemaker W et al. Tissue oxygen debt as a determinant of lethal and nonlethal postoperative organ failure. Crit Care Med 1988; 16:1117-1120.
2. Vermeulen H et al. Intravenous fluid restriction after major abdominal surgery: A randomized blinded clinical trial. Trials 2009; 10:50.
3. Rivers E et al. Early goal directed therapy in the treatment of severe sepsis and septic shock. NEJM 2001; 345:1368-1377.
4. Gustafsson UO et al. Enhanced Recovery after Surgery Society. Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations. Clin Nutr. 2012;31:783-800.
5. Corcoran T et al. Perioperative Fluid Management Strategies in Major Surgery: A stratified meta-analysis. Anesth Analg 2012; 114:640-651.
6. Boyd J et al. Vasopressin in Septic Shock Trial (VASST). Critical Care Medicine 2011; 39:259-265.
7. Vincent JL et al. Sepsis in European ICU: Results of the SOAP Study. Critical Care Med 2006; 34:344-353.
8. Kelm D et al. Fluid overload in patients with severe sepsis and septic shock treated with early goal directed therapy is associated with increased acute need for fluid-related medical interventions and hospital death. Shock 2015; 43:680-73.
Could HighCape be the right partner for your growing business?
Contact us for more information.
452 5th Ave, 21st Floor
New York, NY 10018